XY0206
/ Shijiazhuang Yiling Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
November 03, 2023
A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
(ASH 2023)
- P1 | "XY0206 is a novel FLT3 inhibitor that showed a good safety profile, a potent anti-leukemic activity and improved efficacy in patients with FLT3mut+ R/R AML."
Clinical • P1/2 data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Neutropenia • Oncology • FLT3
September 10, 2025
XY0206-CQT: A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
(clinicaltrials.gov)
- P1 | N=45 | Recruiting | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
February 12, 2025
A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese Men
(clinicaltrials.gov)
- P1 | N=6 | Completed | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
New P1 trial
October 25, 2023
Yiling Pharmaceutical’s clinical trial application for innovative chemical drug XY0206 tablets was approved [Google translation]
(Shanghai Securities News)
- "Shanghai Securities News China Securities Network reported on October 24 that Yiling Pharmaceutical announced that the company recently received the 'Drug Clinical Trial Approval Notice' approved and issued by the State Food and Drug Administration. The drug XY0206 tablets meet the relevant requirements for drug registration. Agree Conduct clinical trials of combination chemotherapy for acute myeloid leukemia....In 2017, the clinical trial application for XY0206 tablets for single-use treatment of acute myeloid leukemia (AML) was approved by the State Food and Drug Administration and has now entered Phase III clinical trials."
New P3 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
August 15, 2023
Yiling Pharmaceutical: XY0206 drug clinical trial application accepted [Google translation]
(Eastmoney.com)
- "...Yiling Pharmaceutical Announcement, innovative medicine of chemical medicine The clinical trial application for XY0206 tablets was accepted. The drug is indicated for the treatment of untreated acute myeloid leukemia (AML) with FLT3-ITD mutation in combination with chemotherapy."
New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
May 25, 2023
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
(clinicaltrials.gov)
- P3 | N=312 | Not yet recruiting | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
New P3 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • FLT3
May 18, 2023
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd | Trial completion date: Dec 2022 ➔ Feb 2024 | Trial primary completion date: Jul 2022 ➔ Feb 2024
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
September 05, 2018
A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours
(clinicaltrials.gov)
- P1; N=34; Not yet recruiting; Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
Clinical • New P1 trial • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Thoracic Cancer • KDR
August 21, 2020
A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours
(clinicaltrials.gov)
- P1; N=34; Recruiting; Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • KDR
September 22, 2020
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1; N=60; Recruiting; Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • F2
July 14, 2020
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1; N=60; Not yet recruiting; Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
Clinical • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
1 to 11
Of
11
Go to page
1